Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study.
Fiche publication
Date publication
novembre 2022
Journal
Journal of clinical medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
Burgevin A, Caron B, Sasson A, Luc A, Netter P, Baumann C, Ananthakrishnan AN, Peyrin-Biroulet L
Lien Pubmed
Résumé
Data about the safety of vedolizumab and ustekinumab are lacking in older patients with inflammatory bowel disease. The objective was to compare the safety of vedolizumab and ustekinumab therapies in older patients (>60 years) with inflammatory bowel disease.
Mots clés
Crohn’s disease, biologics, older, safety, ulcerative colitis
Référence
J Clin Med. 2022 11 25;11(23):